TaiMed BiologicsROCO:4147 55 Current Ratio is 13.11 as of Dec. 2025, which is 25% above its 10-year median of 10.53. GuruFocus rates ROCO:4147 with a GF Score™ of 55/100 and a GF Value™ of NT$85.90 (Modestly Undervalued). Among 1,410 Biotechnology companies, TaiMed Biologics ranks better than 83.69% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. TaiMed Biologics's current ratio for the quarter that ended in Dec. 2025 was 13.11.
TaiMed Biologics has a current ratio of 13.11. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for TaiMed Biologics's Current Ratio or its related term are showing as below:
ROCO:4147'
s Current Ratio Range Over the Past 10 Years
Min: 5.74 Med: 10.53 Max: 73.67
Current: 13.11
During the past 13 years, TaiMed Biologics's highest Current Ratio was 73.67. The lowest was 5.74. And the median was 10.53.
ROCO:4147's Current Ratio is ranked better than 83.69% of 1410
companies
in the Biotechnology industry
Industry Median: 3.89
vs ROCO:4147: 13.11
TaiMed Biologics (ROCO:4147) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
TaiMed Biologics Current Ratio Related Terms
TaiMed Biologics Current Ratio Historical Data
* Premium members only.
The historical data trend for TaiMed Biologics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4147 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, TaiMed Biologics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TaiMed Biologics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TaiMed Biologics's Current Ratio distribution charts can be found below:
* The bar in red indicates where TaiMed Biologics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TaiMed Biologics (ROCO:4147) has a Current Ratio of 13.11 as of Dec. 2025. This is 25% above median its historical median of 10.53. Over the past decade, TaiMed Biologics' Current Ratio has ranged from 5.74 to 73.67. According to the industry distribution chart, TaiMed Biologics ranks #230 out of 1410 companies in the Biotechnology industry, placing it in the top 16.3%.
Is TaiMed Biologics' Current Ratio too high?
TaiMed Biologics' current Current Ratio of 13.11 is 25% above median its 10-year median of 10.53. Over the past 10 years, this metric has ranged from a low of 5.74 to a high of 73.67. The Biotechnology industry median Current Ratio is 3.89. TaiMed Biologics' value of 13.11 is 237% above this industry median. Based on the distribution chart, TaiMed Biologics ranks #230 out of 1410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, TaiMed Biologics has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiMed Biologics' Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TaiMed Biologics ranks #230 out of 1410 companies for Current Ratio. This places TaiMed Biologics in the top 16% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. TaiMed Biologics' value of 13.11 is 237% above this benchmark. Historically, TaiMed Biologics' own Current Ratio has ranged from 5.74 to 73.67 over the past decade. While the company's 10-year median is 10.53 vs. the industry median of 3.89, TaiMed Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TaiMed Biologics's current Current Ratio of 13.11 is 237% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TaiMed Biologics's current Current Ratio is 13.11, which is 25% above median its own 10-year median of 10.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiMed Biologics stock overvalued right now?
Based on GuruFocus' analysis, TaiMed Biologics (ROCO:4147) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$85.90, compared to a current price of NT$69.50 — trading 19.1% below its estimated fair value. The current Current Ratio is 13.11, which is 25% above median its 10-year median of 10.53 and 237% above the Biotechnology industry median of 3.89. TaiMed Biologics' overall GF Score™ is 55/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For TaiMed Biologics (ROCO:4147), the current Current Ratio is 13.11 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TaiMed Biologics (ROCO:4147) Overvalued in 2026?
Based on GuruFocus' analysis, TaiMed Biologics stock appears to be undervalued.
The current stock price of NT$69.50 is trading 19.1% below its estimated GF Value™ of NT$85.90.
GuruFocus considers TaiMed Biologics to be Modestly Undervalued.
Key valuation signals for ROCO:4147:
Current Ratio: 13.11 (25% above median its 10-year median of 10.53)
GF Value™: NT$85.90 vs. price of NT$69.50 (19.1% below fair value)
Industry Position: 237% above the Biotechnology median (#230 of 1410)
No single metric tells the full story. See the ROCO:4147 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TaiMed Biologics Inc is a biotechnology company engaged in developing, manufacturing, and commercializing new drugs for the treatment and prevention of infectious diseases. Its products include Trogarzo IV Infusion, Trogarzo IV Push, TMB-365, TMB-365/TMB-380 combination, and Antibody-Drug Conjugates (ADCs). The Group operates in the Americas, which generates maximum revenue, as well as Europe and Taiwan.
55GF Score
Get the complete analysis for ROCO:4147
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4147 has been successfully added to your 
